Evidence map›Paper›PMID 27708719›Full record

ArticleDiabetes management (London, England)2015

Th17 cells in Type 1 diabetes: a future perspective.

Laura A Solt, Thomas P Burris

Abstract read
In one paragraph

Article in Diabetes management (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Mast Cells as Important Regulators in Autoimmunity and Cancer Development.Frontiers in cell and developmental biology · 2021
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Pleiotropic roles of the insulin-like growth factor axis in type 1 diabetes.Current opinion in endocrinology, diabetes, and obesity · 2019
    Review
  12. IL-17 and limits of success.Cellular immunology · 2019
    Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Laura A SoltDepartment of Molecular Therapeutics, The Scripps Research Institute, 130 Scripps Way, 1B2, Jupiter, FL 33458, USA.
Thomas P BurrisDepartment of Pharmacological & Physiological Science, Saint Louis University School of Medicine, 1402 South Grand Blvd, St. Louis, MO 63104, USA.

Funding

Development of ROR ligands for treatment of circadian rhythm disordersR01MH092769 · NIMH · ST. LOUIS COLLEGE OF PHARMACY · PI BURRIS, THOMAS P, WALKER, JOHN K. · 2011 to 2020
$6.1M
Investigating the Mechanisms Regulating RORgamma ActivityF32DK088499 · NIDDK · SCRIPPS RESEARCH INSTITUTE, THE · PI SOLT, LAURA A · 2010 to 2013
$124k
NIDDK NIH HHS F32 DK088499NIMH NIH HHS R01 MH092769United States NIMH
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

autoimmunitydrug discoveryIL17nuclear receptororphan receptorTh17 cell

Identifiers

PMID27708719
PMCPMC5046833

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.